Cargando…

Acute encephalomyelitis in a 52-year-old male post messenger ribonucleic acid severe acute respiratory syndrome coronavirus 2 vaccination: a case report

BACKGROUND: Acute disseminated encephalomyelitis is a well-known, but rare, side effect of some vaccines, or symptom following a febrile illness. CASE: A 69-year-old, otherwise healthy Hispanic male presented with acute fever, confusion, and later progressive weakness after receiving the first dose...

Descripción completa

Detalles Bibliográficos
Autores principales: Alebna, Pamela Lamisi, Shahid, Muhammad Ahmad, Brannan, Timothy, Shen, Ting, Marian, Valentin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10159673/
https://www.ncbi.nlm.nih.gov/pubmed/37143149
http://dx.doi.org/10.1186/s13256-023-03831-2
_version_ 1785037151534055424
author Alebna, Pamela Lamisi
Shahid, Muhammad Ahmad
Brannan, Timothy
Shen, Ting
Marian, Valentin
author_facet Alebna, Pamela Lamisi
Shahid, Muhammad Ahmad
Brannan, Timothy
Shen, Ting
Marian, Valentin
author_sort Alebna, Pamela Lamisi
collection PubMed
description BACKGROUND: Acute disseminated encephalomyelitis is a well-known, but rare, side effect of some vaccines, or symptom following a febrile illness. CASE: A 69-year-old, otherwise healthy Hispanic male presented with acute fever, confusion, and later progressive weakness after receiving the first dose of the mRNA-1273 (Moderna) severe acute respiratory syndrome coronavirus 2 vaccine. Considering the progressive deterioration of the patient, despite being on multiple immunosuppressive agents, a brain biopsy was obtained, which revealed nonspecific meningoencephalitis. CONCLUSION: In this case, we highlight the need for a regulatory framework to assist clinicians and patients with coverage of treatment for acute disseminated encephalomyelitis. The use of intravenous immunoglobulin in conjunction with glucocorticoids seems to be an effective treatment option.
format Online
Article
Text
id pubmed-10159673
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-101596732023-05-06 Acute encephalomyelitis in a 52-year-old male post messenger ribonucleic acid severe acute respiratory syndrome coronavirus 2 vaccination: a case report Alebna, Pamela Lamisi Shahid, Muhammad Ahmad Brannan, Timothy Shen, Ting Marian, Valentin J Med Case Rep Case Report BACKGROUND: Acute disseminated encephalomyelitis is a well-known, but rare, side effect of some vaccines, or symptom following a febrile illness. CASE: A 69-year-old, otherwise healthy Hispanic male presented with acute fever, confusion, and later progressive weakness after receiving the first dose of the mRNA-1273 (Moderna) severe acute respiratory syndrome coronavirus 2 vaccine. Considering the progressive deterioration of the patient, despite being on multiple immunosuppressive agents, a brain biopsy was obtained, which revealed nonspecific meningoencephalitis. CONCLUSION: In this case, we highlight the need for a regulatory framework to assist clinicians and patients with coverage of treatment for acute disseminated encephalomyelitis. The use of intravenous immunoglobulin in conjunction with glucocorticoids seems to be an effective treatment option. BioMed Central 2023-05-05 /pmc/articles/PMC10159673/ /pubmed/37143149 http://dx.doi.org/10.1186/s13256-023-03831-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Case Report
Alebna, Pamela Lamisi
Shahid, Muhammad Ahmad
Brannan, Timothy
Shen, Ting
Marian, Valentin
Acute encephalomyelitis in a 52-year-old male post messenger ribonucleic acid severe acute respiratory syndrome coronavirus 2 vaccination: a case report
title Acute encephalomyelitis in a 52-year-old male post messenger ribonucleic acid severe acute respiratory syndrome coronavirus 2 vaccination: a case report
title_full Acute encephalomyelitis in a 52-year-old male post messenger ribonucleic acid severe acute respiratory syndrome coronavirus 2 vaccination: a case report
title_fullStr Acute encephalomyelitis in a 52-year-old male post messenger ribonucleic acid severe acute respiratory syndrome coronavirus 2 vaccination: a case report
title_full_unstemmed Acute encephalomyelitis in a 52-year-old male post messenger ribonucleic acid severe acute respiratory syndrome coronavirus 2 vaccination: a case report
title_short Acute encephalomyelitis in a 52-year-old male post messenger ribonucleic acid severe acute respiratory syndrome coronavirus 2 vaccination: a case report
title_sort acute encephalomyelitis in a 52-year-old male post messenger ribonucleic acid severe acute respiratory syndrome coronavirus 2 vaccination: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10159673/
https://www.ncbi.nlm.nih.gov/pubmed/37143149
http://dx.doi.org/10.1186/s13256-023-03831-2
work_keys_str_mv AT alebnapamelalamisi acuteencephalomyelitisina52yearoldmalepostmessengerribonucleicacidsevereacuterespiratorysyndromecoronavirus2vaccinationacasereport
AT shahidmuhammadahmad acuteencephalomyelitisina52yearoldmalepostmessengerribonucleicacidsevereacuterespiratorysyndromecoronavirus2vaccinationacasereport
AT brannantimothy acuteencephalomyelitisina52yearoldmalepostmessengerribonucleicacidsevereacuterespiratorysyndromecoronavirus2vaccinationacasereport
AT shenting acuteencephalomyelitisina52yearoldmalepostmessengerribonucleicacidsevereacuterespiratorysyndromecoronavirus2vaccinationacasereport
AT marianvalentin acuteencephalomyelitisina52yearoldmalepostmessengerribonucleicacidsevereacuterespiratorysyndromecoronavirus2vaccinationacasereport